LGP2 Protein, Human (HEK293, His, StrepⅡ, FLAG)

LGP2 protein is a key regulator of RIGI- and IFIH1/MDA5-mediated antiviral signaling and has dual negative and positive functions affected by factors such as infected viruses and target cells. LGP2 lacks a CARD domain for independent initiation of antiviral signaling and therefore inhibits RIG-I through multiple mechanisms, including competition for RNA binding and obstruction of interaction with MAVS/IPS1. LGP2 Protein, Human (HEK293, His, Strep, FLAG) is the recombinant human-derived LGP2 protein, expressed by HEK293 , with N-Strep, C-Flag, N-8*His labeled tag.

LGP2 Protein functions as a key regulator of RIGI and IFIH1/MDA5-mediated antiviral signaling, contributing both negative and positive regulatory functions that are contingent on various factors such as the infecting virus, target cells, or a combination of both. Lacking the CARD domain necessary for activating MAVS/IPS1-dependent signaling events, LGP2 cannot initiate antiviral signaling on its own. Its inhibitory effects on RIG-I signaling may involve multiple mechanisms, including competition with RIGI for binding to viral RNA, direct binding to RIGI to impede dimerization and interaction with MAVS/IPS1, and competition with IKBKE for binding to MAVS/IPS1, thereby hindering IRF3 activation. Conversely, its positive regulatory role may encompass activities such as unwinding or stripping nucleoproteins from viral RNA, thereby facilitating recognition by RIGI and IFIH1/MDA5. LGP2 plays a crucial role in the innate immune response to various RNA viruses, DNA viruses like poxviruses and coronavirus SARS-CoV-2, as well as the bacterial pathogen Listeria monocytogenes, highlighting its versatile involvement in antiviral defense. The protein exhibits affinity for both single-stranded and double-stranded RNA, with a preference for 5'-triphosphorylated RNA, although it can recognize RNA lacking this modification.

Human

HEK293

N-StrepⅡ;N-8*His;C-Flag

Q96C10 (M1-D678)

79132

Greater than 90% as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.